Investigating the Generalizing Effects of PTSD Group Treatment: A Trial With Veterans
Friday, November 17
3:30 PM - 5:00 PM
Location: Sapphire Ballroom B, Level 4, Sapphire Level
Keywords: PTSD Posttraumatic Stress Disorder | Randomized Controlled Trial | Psychotherapy Outcome
Presentation Type: Symposium
PTSD is a highly prevalent disorder, especially among military service members and veterans. In fact, PTSD is the most common psychiatric condition for which veterans seek mental health services. Despite the high rate of secondary comorbid psychiatric conditions among veterans diagnosed with PTSD, most PTSD treatment studies only examine PTSD outcome. It is important to investigate whether efficacious PTSD treatment also leads to reductions in secondary comorbid condition, such as depression and substance use disorders.
In this presentation, Dr. Sloan will describe outcome results of a RCT comparing a Group CBT (GCBT) with Group Present Centered Therapy (GPCT) for chronic PTSD. GCBT included exposure, cognitive restructuring, anxiety management, and activity scheduling, in addition to nurturing group cohesion. GPCT included psychoeducation, peer support, and peer-facilitated problem solving. The sample included 198 male veterans. Approximately 75% of the veterans were Caucasian with an average age of 55. Assessments occurred pre-, mid-, and post-treatment, and at 3-and 6- months follow-up. Although the primary aim of the study is to examine the effects of GCBT on PTSD outcome, the secondary aim is to examine the generalizing effects of PTSD treatment on comorbid conditions, including depression, substance use disorders and anxiety disorders. A semi-structured clinical interview was used to assess for comorbidity (SCID) in addition to self-report measures (e.g., BDI-II and BAI). Results are not available at this time as the follow-up assessment phase will be completed within the next month. We will examine whether PTSD treatment results in significant reductions in depression, anxiety, and harmful alcohol use. Results will be discussed in light of the available data investigating the efficacy of PTSD treatment on comorbid conditions.